M Ahluwalia,R O&#x;Quinn,B Ky et al.
M Ahluwalia et al.
Background: Electrocardiographic changes may manifest in patients with pericardial effusions. PR segment changes are frequently overlooked, but when present, can provide diagnostic significance. The diagnostic value of PR...
Baseline global longitudinal strain predictive of anthracycline-induced cardiotoxicity [0.03%]
基线纵向应变预测蒽环类药物所致心脏毒性
Raquel Araujo-Gutierrez,Kalyan R Chitturi,Jiaqiong Xu et al.
Raquel Araujo-Gutierrez et al.
Background: Cancer therapy-related cardiac dysfunction (CTRD) is a major source of morbidity and mortality in long-term cancer survivors. Decreased GLS predicts decreased left ventricular ejection fraction (LVEF) in patie...
Healthcare disparities in cardio oncology: patients receive same level of surveillance regardless of race at a safety net hospital [0.03%]
心脏肿瘤学中的医疗不平等：在一个安全网医院中，患者接受的监测水平与种族无关
Crystal B Chen,Raj K Dalsania,Eman A Hamad
Crystal B Chen
Background: Cardiotoxicity remains a dreaded complication for patients undergoing chemotherapy with human epidermal growth factor (HER)-2 receptor antagonists and anthracyclines. Though many studies have looked at racial ...
A virtual-hybrid approach to launching a cardio-oncology clinic during a pandemic [0.03%]
疫情期间启动心血管肿瘤科门诊的虚拟混合方法
Sherry-Ann Brown,Sahishnu Patel,David Rayan et al.
Sherry-Ann Brown et al.
Background: As cardiovascular disease is a leading cause of death in cancer survivors, the new subspecialty of Cardio-Oncology has emerged to address prevention, monitoring, and management of cardiovascular toxicities to ...
A case report: rapid progression of coronary atherosclerosis in a patient taking Targretin (Bexarotene) [0.03%]
他可林引起的冠脉粥样硬化进展一例报告
Sean DeAngelo,Kailyn I Mann,Muhammad Abdulbasit et al.
Sean DeAngelo et al.
Anti-neoplastic drugs have made major advancements in oncology, however they are not without cardiovascular consequences. We present a patient with cutaneous T-cell lymphoma receiving Targretin therapy who presented with accelerated atheros...
The prevalence of iron deficiency and anemia and their impact on survival in patients at a cardio-oncology clinic [0.03%]
心脏肿瘤学诊所患者缺铁和贫血的流行率及其对生存的影响
E Čiburienė,J Čelutkienė,S Aidietienė et al.
E Čiburienė et al.
Background: Iron deficiency (ID) and anemia are common in both heart failure (HF) and cancer patients and are associated with poor quality of life and survival. The aims of this study were (1) to evaluate the prevalence, ...
Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer [0.03%]
曲妥珠单抗治疗乳腺癌患者的治疗中断对临床的影响研究
Sagar Sardesai,Jasmine Sukumar,Mahmoud Kassem et al.
Sagar Sardesai et al.
Background: Trastuzumab-induced cardiotoxicity (TIC) can lead to early discontinuation of adjuvant therapy, however there is limited evidence on long-term survival outcomes in patients with operable human epidermal growth...
Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey [0.03%]
COVID-19国际协作网络调查影响心脏肿瘤学的新冠肺炎疫情观点
Diego Sadler,Jeanne M DeCara,Joerg Herrmann et al.
Diego Sadler et al.
Background: Re-allocation of resources during the COVID-19 pandemic has resulted in delays in care delivery to patients with cardiovascular disease and cancer. The ability of health care providers to provide optimal care ...
Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy [0.03%]
卡托普利/缬沙坦在化疗相关心脏毒性和心力衰竭患者中的应用
Vanesa Gregorietti,Teresa Lopez Fernandez,Diego Costa et al.
Vanesa Gregorietti et al.
Background: Cancer therapy-related cardiac dysfunction (CTRCD) is a critical problem with an impact on both oncological and cardiovascular prognosis, especially when it prevents patients from receiving cancer treatment. S...
Massimiliano Camilli,Marco Giuseppe Del Buono,Pierantonio Menna et al.
Massimiliano Camilli et al.
Sacubitril/Valsartan (S/V) is a novel and remarkably effective opportunity to treat heart failure with reduced ejection fraction (HFrEF). However, patients with HFrEF induced by cancer therapy were a priori excluded from the registration st...